Skip to main content
. Author manuscript; available in PMC: 2022 Jan 18.
Published in final edited form as: Gynecol Oncol. 2015 Sep 30;139(3):553–558. doi: 10.1016/j.ygyno.2015.09.079

Table 6.

ESAS scores at baseline and follow-up visits

ESAS variable Baseline ESAS score, median (IQR)
N=35
FUESAS score, median (IQR)
N = 35
P Number of patients with baseline ESAS score≥4 (%) Baseline ESAS score in patients with baseline ESAS≥4, median (IQR) FUESAS score in patients with baseline ESAS≥4, median (IQR) P
Pain 6 (4–8) 6 (3–9) 0.536 30 (85.7) 7 (6–8) 6.5 (4–8) 0.087
Fatigue 5 (3–8) 5 (3–7) 0.599 22 (62.9) 7 (6–8) 5 (4–8) 0.076
Nausea 1 (0–5) 1 (0–4) 0.502 11 (31.4) 6 (5–9) 3 (1–4) 0.006
Depression 2 (0–4) 1 (0–3) 0.174 13 (37.1) 5 (4–6) 2 (0–7) 0.042
Anxiety 3 (0–5) 1 (0–3) 0.078 16 (45.7) 5 (4–8) 2 (0–5) 0.004
Drowsiness 3 (0–5) 3 (0–4) 0.707 13 (38.2) 5 (5–7) 3 (3–5) 0.124
Dyspnea 0 (0–2) 0 (0–3) 0.660 6 (17.1) 5 (4–6) 2 (1–3) 0.063
Anorexia 5 (3–8) 5 (3–7) 0.787 22 (64.7) 6 (5–9) 5 (4–8) 0.100
Feeling of well-being 5 (3–7) 4 (3–7) 0.299 25 (73.5) 6 (5–7) 4 (3–7) 0.028
Sleep 4 (2–6) 5 (3–7) 0.257 18 (52.9) 6 (6–8) 7 (5–8) 0.887
SDS 33 (21–44) 27 (20–35) 0.167 --- --- --- ---

Abbreviations: ESAS, Edmonton Symptom Assessment System; FU, follow-up; IQR, interquartile range;